SCHEMBL9513831

SCHEMBL9513831

CCN(C)Cc1ccc(Cl)cc1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PYCR1 P32322 1/20 0.60
P2RX7 Q99572 1/20 0.50
LSS P48449 3/20 0.49
ALDH1A1 P00352 2/20 0.48
HTT P42858 1/20 0.48
RAB9A P51151 1/20 0.48
KDM4E B2RXH2 2/20 0.47
TSHR P16473 1/20 0.47
CHRNB2 P17787 1/20 0.47
CHRNA4 P43681 1/20 0.47
TMEM97 Q5BJF2 1/20 0.46
SIGMAR1 Q99720 1/20 0.46
AOC3 Q16853 1/20 0.45
F10 P00742 1/20 0.43
CXCR3 P49682 1/20 0.43
CNR2 P34972 2/20 0.42
CNR1 P21554 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18532755 0.88 PYCR1 (0.67) PYCR1P2RX7LSSALDH1A1HTT
SCHEMBL12763726 0.88 CHRNB2 (0.56) PYCR1ALDH1A1KDM4ECHRNB2CHRNA4
SCHEMBL14006726 0.83 PYCR1 (0.56) PYCR1P2RX7LSSALDH1A1HTT
SCHEMBL12910454 0.81 CHRNB2 (0.50) PYCR1ALDH1A1KDM4ETSHRCHRNB2
SCHEMBL10663042 0.80 PYCR1 (0.58) PYCR1P2RX7LSSALDH1A1HTT
SCHEMBL9131306 0.79 TMEM97 (0.56) PYCR1KDM4ETSHRTMEM97SIGMAR1
SCHEMBL11366830 0.79 HRH3 (0.67) PYCR1ALDH1A1HTTRAB9A
SCHEMBL7297585 0.79 PYCR1 (0.59) PYCR1ALDH1A1KDM4ECHRNB2CHRNA4
SCHEMBL12837021 0.79 HRH3 (0.67) PYCR1ALDH1A1KDM4ECHRNB2CHRNA4
SCHEMBL7158728 0.78 AOC3 (0.62) PYCR1P2RX7LSSALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021101919-A1 COMPOUNDS USEFUL AS INHIBITORS OF HELIOS PROTEIN BRISTOL-MYERS SQUIBB COMPANY (US) 2021-05-27 WO disclosed
EP-3456713-A1 PROCESS FOR THE PREPARATION OF TRIAZINE DERIVATIVES Japan Tobacco Inc. (JP) 2019-03-20 EP disclosed
US-20110281837-A1 3-SUBSTITUTED-6-ARYL PYRIDINES HUTCHINSON ALAN J (US) 2011-11-17 US disclosed
US-7863454-B2 3-substituted-6-aryl pyridines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2011-01-04 US disclosed
US-20090176980-A1 3-Substituted-6-Aryl Pyridines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2009-07-09 US disclosed
US-7342115-B2 Binding antagonist and arylpyridine for antiinflammatory agents, cardiovascular disorders and antagonist or agonist and for immunology NEUROGEN CORPORATION (US) 2008-03-11 US disclosed
EP-0355351-B1 Process for the preparation of amines BAYER AG (DE) 1993-11-10 EP disclosed
US-5011996-A Process for the preparation of amines BAYER AKTIENGESELLSCHAFT (DE) 1991-04-30 US disclosed
EP-0355351-A2 Process for the preparation of amines BAYER AG (DE) 1990-02-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281837-A1 3-SUBSTITUTED-6-ARYL PYRIDINES C3AR1, C5AR1, C5AR2 PYCR1 786/4885P2RX7 16/4885LSS 4072/4885
US-20090176980-A1 3-Substituted-6-Aryl Pyridines C3AR1, C5AR1, C5AR2 PYCR1 786/4885P2RX7 16/4885LSS 4072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.